Travere Therapeutics (TVTX) Asset Utilization Ratio (2014 - 2026)
Travere Therapeutics posted quarterly Asset Utilization Ratio of 0.12 for Q1 2026, down 125.24% year-on-year from 0.48 in Q1 2025, and up 40.21% on a QoQ basis from 0.2 in Q4 2025.
Travere Therapeutics (TVTX) has 13 years of Asset Utilization Ratio data on file, last reported at 0.12 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio fell 125.24% year-over-year to 0.12; the trailing twelve-month figure through Mar 2026 stood at 0.12 (down 125.24% YoY), and the FY2025 full-year result was 0.02, down 95.4% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.12, up from 0.2 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.6 in Q2 2025 and bottomed at 0.2 in Q4 2025.
- The 5-year median for Asset Utilization Ratio is 0.17 (2023), against an average of 0.19.
- The widest annual swing landed in 2022, when Asset Utilization Ratio jumped 10077.44%; it then slumped 147.6% in 2025.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.16 in 2022, then climbed by 14.44% to 0.18 in 2023, then surged by 137.01% to 0.42 in 2024, then plunged by 147.6% to 0.2 in 2025, then jumped by 40.21% to 0.12 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.12 (Q1 2026), 0.2 (Q4 2025), and 0.57 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.85 |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | -0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.12 |
| Dec 31, 2025 | -0.20 |
| Sep 30, 2025 | 0.57 |
| Jun 30, 2025 | 0.60 |
| Mar 31, 2025 | 0.48 |
| Dec 31, 2024 | 0.42 |
| Sep 30, 2024 | 0.39 |
| Jun 30, 2024 | 0.29 |
| Mar 31, 2024 | 0.21 |
| Dec 31, 2023 | 0.18 |
| Sep 30, 2023 | 0.17 |
| Jun 30, 2023 | 0.16 |
| Mar 31, 2023 | 0.16 |
| Dec 31, 2022 | 0.16 |
| Sep 30, 2022 | -0.10 |
| Jun 30, 2022 | -0.06 |
| Mar 31, 2022 | -0.03 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 0.27 |
| Jun 30, 2021 | 0.27 |
| Mar 31, 2021 | 0.29 |
| Dec 31, 2020 | 0.31 |
| Sep 30, 2020 | 0.28 |
| Jun 30, 2020 | 0.30 |
| Mar 31, 2020 | 0.31 |
| Dec 31, 2019 | 0.29 |
| Sep 30, 2019 | 0.27 |
| Jun 30, 2019 | 0.26 |
| Mar 31, 2019 | 0.24 |
| Dec 31, 2018 | 0.23 |
| Sep 30, 2018 | 0.27 |
| Jun 30, 2018 | 0.33 |
| Mar 31, 2018 | 0.31 |
| Dec 31, 2017 | 0.30 |
| Sep 30, 2017 | 0.29 |
| Jun 30, 2017 | 0.28 |
| Mar 31, 2017 | 0.27 |
| Dec 31, 2016 | 0.25 |
| Sep 30, 2016 | 0.24 |
| Jun 30, 2016 | 0.23 |
| Mar 31, 2016 | 0.22 |
| Dec 31, 2015 | 0.20 |
| Sep 30, 2015 | 0.18 |
| Jun 30, 2015 | 0.15 |
| Mar 31, 2015 | 0.17 |
| Dec 31, 2014 | 0.20 |